bluebird bio (BLUE) Stock Price, News & Analysis (2024)

FAQs

Bluebird bio (BLUE) Stock Price, News & Analysis? ›

What are analysts forecasts for bluebird bio stock? The 31 analysts offering price forecasts for bluebird bio have a median target of 6.22, with a high estimate of 13.00 and a low estimate of 1.02. The median estimate represents a 14.44 difference from the last price of 0.90.

Average Price Target

Based on 11 Wall Street analysts offering 12 month price targets for Bluebird Bio in the last 3 months. The average price target is $3.67 with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 298.05% change from the last price of $0.92.

Blue Bird Corp's analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

According to our current BLUE stock forecast, the value of bluebird bio shares will rise by 5.73% and reach $ 0.937946 per share by May 6, 2024.

On average, Wall Street analysts predict that Bluebird Bio's share price could reach $5.71 by Mar 27, 2025. The average Bluebird Bio stock price prediction forecasts a potential upside of 528.49% from the current BLUE share price of $0.91.

Shares of bluebird were down 17% at $1.12 in morning trading. The company said it incorrectly separated the lease and non-lease components of some of the contracts in its reporting, resulting in an estimated understatement of lease assets and liabilities between $100 million and $200 million in 2022.

Top Shareholders

The Vanguard Group, Inc. Alyeska Investment Group, L.P. State Street Global Advisors, Inc. Farallon Capital Management, L.L.C.

In total, the biotech anticipates between 85 and 105 patient starts across its three therapies in 2024. Bluebird Bio thinks it has enough cash to last until the first quarter of 2025.

Valuation metrics show that bluebird bio, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors.

The stock split occured on November 5th, 2021.

How many employees does bluebird bio have? ›

Total revenue, net was $29.5 million for the twelve months ended December 31, 2023 , compared to $3.6 million for the twelve months ended December 31, 2022 .

BIO Stock Forecast FAQ

Bio-Rad Laboratories has 53.93% upside potential, based on the analysts' average price target. Is BIO a Buy, Sell or Hold? Bio-Rad Laboratories has a conensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

According to the current price, bluebird bio is 16.28% away from the 52-week high. What are analysts forecasts for bluebird bio stock? The 31 analysts offering price forecasts for bluebird bio have a median target of 6.22, with a high estimate of 13.00 and a low estimate of 1.02.

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock.

Allbirds stock has received a consensus rating of buy.

Blue Bird stock prediction for 1 year from now: $ 42.06 (23.80%) Blue Bird stock forecast for 2025: $ 39.41 (16.01%) Blue Bird stock prediction for 2030: $ 82.82 (143.80%)

Overall, 60% of employees would recommend working at bluebird bio to a friend. This is based on 179 anonymously submitted reviews on Glassdoor. How do job seekers rate their interview experience at bluebird bio? 46% of job seekers rate their interview experience at bluebird bio as positive.

Non-serious adverse events (AEs) observed during clinical studies that were attributed to beti-cel included abdominal pain, thrombocytopenia, leukopenia, neutropenia, hot flush, dyspnea, pain in extremity, tachycardia and non-cardiac chest pain.

Based on analyst ratings, Allbirds's 12-month average price target is $1.00. What is BIRD's upside potential, based on the analysts' average price target? Allbirds has 63.24% upside potential, based on the analysts' average price target.